The distinguished translational oncology researchers on Unum’s Scientific Advisory Board (SAB) provide counsel to support continued development of our ACTR platform, and provide us with key insights as we develop our broader research agenda. Comprised of pioneers in immuno-oncology, our SAB includes:
Dario Campana, MD, PhD
Malcom Brenner, MD, PhD
John Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Crystal Mackall, MD
Malcolm Brenner, MD, PhD
Dr. Brenner’s career has focused on gene therapy and cancer-related immunotherapies, including genetic-modification of T cells. He is currently the founding director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital. In his prior work at St. Jude Children's Research Hospital, he conducted one of the first human gene therapy studies, using a retroviral vector to transduce bone marrow stem cells. He has also served as President of the International Society for Cellular Therapy; President of the American Society of Gene Therapy; and Editor-in-Chief of the journal Molecular Therapy.